PUBLICATIONS

Books and Monographs Published (Book Chapters):


Juried or Refereed Journal Articles:


Horstman LL, Jy W, Jimenez JJ, Bidot C and Ahn YS. New horizons in the analysis of circulating cell-derived microparticles (Review). *Keio J Med [Tokyo]* 53(4): 210-230, 2004. (Lectures delivered to *Japan Society of Hematology* (Nov. 28) and *Keio School of Medicine* (Dec 1); invited for publication by Editor)


**Other Works: Presentations at Natíl / Internatíl Conferences:**


Ahn YS, Horstman LL, Fontana V, Jimenez JJ and Ahn ER, Microparticles from RBC (RMP) exhibit hemostatic activities in vitro and in vivo, and appear to protect ITP patients from thrombocytopenic bleeding. *Atherosclerosis [Supl.]* **7**(3): 292, Abst Tu-P10:486,


Ahn ER, Podack E, Jy W, Bidot CJ, Horstman LL and Ahn YS, Soluble CD30 (sCD30), a marker of Th2 polarization, is elevated in patients with autoimmune hemolytic anemia (AIHA) but not idiopathic thrombocytopenia (ITP). Blood 106(11): 363a #1248, 2005. [Presented, meeting of the American Society of Hematology (ASH), Dec. 10-13, Atlanta, GA.]


Jy W, Jimenez JJ, Mauro LM, Horstman LL, Bidot CJ, Tiede MP, Ahn ER and Ahn YS, Endothelial microparticles (EMP) interact with platelets via a vWF dependent pathway to form platelet aggregates, more resistant to dissociation than those induced by soluble vWF. *Blood* 102(11): 783a (Ab 2896), 2003. (Presented, 45th ASH meeting, Dec 6-9, San Diego, CA.)

Ahn YS, Jy W, Jimenez JJ and Horstman LL, Endothelial microparticles as a marker of endothelial injury (Presented, 29th International Congress of Hematology; Seoul, Korea, Aug 17.).; 2002. (Presented, 29th International Congress of Hematology; Seoul, Korea, Aug 17.)


Jimenez JJ, Jy W, Mauro LM, Valle MS, Horstman LL and Ahn YS, Activation-derived endothelial microparticles (EMP) are elevated in thrombotic thrombocytopenic purpura (TTP): Detection of von Willebrand factor (vWF)-positive EMP during the acute phase of TTP. *Blood* 100(11): 16a (Abst #47), 2002. (Presented orally 44th ASH mtg, Philadelphia, PA, Dec 6-10.)


Jimenez JJ, Jy W, Horstman LL, Mauro LM, Bernal-Mizrachi L and Ahn YS, TTP plasma induces release of procoagulant EMP (endothelial microparticles) from endothelial cells in culture; and EMP is markedly elevated in patients. *Blood* 96(11,Prt1): 531a(#2283), 2000. (Presented, 42nd ASH mtng, San Francisco, CA, 12/1-5.)


Jy W, Horstman LL, Mao WW and Ahn YS, Increased sensitivity of platelets to complement in immune thrombocytopenia (ITP) and protection by danazol. *La Revista de Investigacion Clinica (suppl):* 214 (a120), 1994. (Presented, XXV Congress of ISH, Cancun, Mexico, Apr 17-22.)


Jy W, Horstman LL and Ahn YS, Stimulation and inhibition of platelet membrane fragmentation.:, 1990. (Presented, ASH mtg, Boston, MA., Dec 4.)


Ahn YS, Harrington WJ, Byrnes JJ and EtAl, Selective chemotherapy in the disorders of MPS.:, 1979.(Presented, 4th Int’l. Soc. Hematol, Asian-Pacific Division, Seoul, Korea, June.)


**Other Works and Publications (Abstracts):**


Chirinos JA, Jy W, DelCarpio F, Arteaga R, Gustavo HA, Valvidia M, Horstman LL, Jimenez JJ and Ahn YS, Correlation between endothelial microparticle binding to monocytes and


Ahn ER, Podack ER, Lander G, Bidot CJ, Jy W and Ahn YS, Soluble CD30 levels are highest in autoimmune hemolytic anemia (AIHA) and lymphoma among hematologic disorders, but are not elevated in ITP. *Blood* 104(11): 55b Ab4748, 2004. (46th ASH, Dec. 4-7, San Diego, CA.)


Arteaga RB, Soriano AO, Chirinos JA, Jy W, Gonzalez M, Yaniz M, Horstman LL, Jimenez JJ and Ahn YS, Elevated endothelial microparticles (EMP) and platelet activation in patients with the metabolic syndrome (MTS) at low to intermediate risk for cardiovascular diseases. *Blood* 102(11): 74b (Ab 4001), 2003. (Forty-fifth annual meeting of ASH, Dec 6-9, San Diego, CA)

Jimenez JJ, Ferreira A, Peter A, Jy W, Mauro LM, Mendez AJ, DeMarchena E, Soderland C, Horstman LL and Ahn YS, Elevated endothelial microparticles (EMP) and decreased endothelial progenitors are associated with increased serum cholesterol levels. *Blood* 102(11): 73b (Ab 3997), 2003. (Forty-fifth annual meeting of ASH, Dec 6-9, San Diego, CA)


Bidot CJ, Jy W, Horstman LL, Jimenez JJ, Yaniz M and Ahn YS, Antiphospholipid antibodies (APA) is a risk factor for thrombosis and factor FVIIa and phosphatidylethanolamine (PE) are most frequent antigens in patients with clonal thrombocytosis (TS) and thrombosis. *Blood* 100(11 Ptt 2): 83b (Abst #3804), 2002.(44th ASH meeting, Philadelphia, PA, Dec 6-10.)


Donna E, Ahn YS, Huang HS, Horstman LL, Jimenez JJ and Jy W, Interstitial lung disease associated with Imatinib (Gleevec) therapy for chronic myelogenous leukemia (CML). *Blood* 100(11 Ptt 2): 327b (Abst #4857), 2002.(44th ASH meeting, Philadelphia, PA, Dec 6-10.)


Soriano A, Ahn YS, Horstman LL, Jimenez JJ, Jy W and Bidot C, Overlapping syndromes of ITP and TTP: Case reports and delineation of the syndrome. *Blood* 100(11 Ptt 2): 81b (Abst #3796), 2002.(44th ASH meeting, Philadelphia, PA, Dec 6-10.)


Valant PA, Jy W, Horstman LL, Mao WW, Schultz DR and Ahn YS, Intravenous immune globulin (IV-IgG) inhibits platelet activation induced by plasma from a thrombotic thrombocytopenic purpura patient. *Blood* 92(Supl)(10): 90b(#3370), 1998.(40th ASH mt'g, Dec 4-8, 1998, Miami, FL)


